Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

In a report released yesterday, William Plovanic from Canaccord Genuity downgraded Inari Medical (NARI – Research Report) to a Hold, with a ...

Fintel reports that on January 7, 2025, William Blair downgraded their outlook for Inari Medical (NasdaqGS:NARI) from ...

Inari Medical (NARI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mathew ...

Irvine-based Inari Medical Inc. has entered into an agreement to be acquired for $4.9 billion by medical technology company ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

On Tuesday, Baird analysts adjusted their stance on Inari Medical (TASE:PMCN) Inc. (NASDAQ:NARI), downgrading the stock from Outperform to Neutral and slightly reducing the price target to $80 ...

Inari Medical's thrombectomy products have been ... have given Inari an Outperform and Buy rating respectively. Inari's ClotTriever Thrombectomy System for deep vein thrombosis has also received ...

while Canaccord Genuity adjusted its stance on Inari Medical, downgrading it from Buy to Hold, but increasing the price target to $80.00. Inari's ClotTriever Thrombectomy System for deep vein ...